Progensa® PCA3

Considering a repeat biopsy for your patient? Confirm negative biopsies with CONFIDENCE. Progensa PCA3 can help.


PCA3 is a prostate-specific gene that is over-expressed in prostate tumors. Prostate cancer cells express 60 to 100 times more PCA3 than normal cells.

Unlike PSA, PCA3 is not influenced by benign prostatic hyperplasia (BPH), prostatitis, medical procedures, or injury.


  • The first urine-based molecular test that delivers confidence to make informed repeat biopsy decisions
  • HIGHLY SPECIFIC – indicates a cancer specificity lacking with PSA alone
  • EASY TO USE – utilizes a FIRST-CATCH urine sample post DRE
  • Extensive CLINICAL DATA
  • FDA approved
  • Included in the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection

Improve your biopsy decisions.
Reduce the number of unnecessary repeat biopsies.

Results delivered within 5 business days of sample receipt.


The Progensa® PCA3 assay is provided to Metamark by Hologic.


Next: ProMark

        Clinical Validation
        Sample Collection and Preparation
        The PCA3 Report
        PCA3 Guidelines

        How to Order
        Billing Information
        Useful Resources